Avobis Bio, LLC

Quick facts

Phase 2 pipeline

• AVB-114 · Diabetes
  AVB-114 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Avobis Bio, LLC portfolio CI brief
• Avobis Bio, LLC pipeline updates RSS